MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival in patients with acute myeloid leukemia or blood cancer receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment. The company was incorporated in 2014 and is headquartered in Lyon, France.
Metrics to compare | MAAT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMAATPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.5x | −1.4x | −0.5x | |
PEG Ratio | 0.09 | 0.02 | 0.00 | |
Price/Book | 6.9x | 1.2x | 2.6x | |
Price / LTM Sales | 22.1x | 4.8x | 3.2x | |
Upside (Analyst Target) | 285.5% | 171.1% | 44.6% | |
Fair Value Upside | Unlock | 5.6% | 6.5% | Unlock |